Strong Growth Potential for Oruka Therapeutics Driven by Robust Financials and Promising Drug Pipeline
LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on ORKA stock, giving a Buy rating today. Sam Slutsky’s rating ...
Promising Prospects for Acurx Pharmaceuticals: Buy Rating Backed by Ibezapolstat’s Efficacy and Strategic Positioning
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Acurx Pharmaceuticals (ACXP – Research ...